Cullinan therapeutics provides corporate update and reports first quarter 2025 financial results

Company received approval from european medicines agency (ema) for cln-978; phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in q2 2025

CGEM Ratings Summary

CGEM Quant Ranking